As Alcon Shareholders Fight Back, Will Novartis Sweeten Its Merger Offer?
This article was originally published in The Gray Sheet
Executive Summary
Independent Alcon shareholders have been holding out for months for a buyout offer from Novartis that is closer to what the latter firm is paying for the majority of the company
You may also be interested in...
Novartis/Alcon Merger Clears FTC Hurdle With Minor Divestiture, But Shareholder Battle Continues
Novartis sells its miotic drug Miochol-E to Bausch & Lomb to avoid anticompetitive charges; a Novartis legal expert says a subset of Alcon's board cannot veto the transaction.
Novartis Completes Deal For Nestle's Share In Alcon
For Novartis, acquiring the first 77% of Alcon might have been the easy part. Novartis said Aug. 26 that it had closed its deal to acquire 52% of Alcon from Nestle for $28.3 billion in cash, on top of the 25% it acquired from the same company in 2008
Novartis Completes Deal For Nestle's Share In Alcon
For Novartis, acquiring the first 77% of Alcon might have been the easy part. Novartis said Aug. 26 that it had closed its deal to acquire 52% of Alcon from Nestle for $28.3 billion in cash, on top of the 25% it acquired from the same company in 2008